BioMarin Hires Pharmaceutical Industry Leaders in Marketing and Accounting to Fill Strategic Roles Supporting Company Growth Plans


Humaira Serajuddin appointed to newly created role of Senior Vice President, Chief Marketing Officer

Erin Burkhartappointed Group Vice President, Chief Accounting Officer

SAN RAFAEL, Calif., May 5, 2022 /PRNewswire/ — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has hired two pharmaceutical industry leaders in their respective areas of expertise. Humaira Serajuddin was appointed Senior Vice President, Chief Marketing Officer and Erin Burkhart was appointed Group Vice President, Chief Accounting Officer, fulfilling two key strategic roles supporting BioMarin’s growth objectives.

BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

“We are delighted to welcome Humaira and Erin to BioMarin at a time of financial, business and regulatory momentum in 2022 and beyond. In their respective strategic roles, they will support product launches and scale the organization for our transition advancement towards sustainable profitability and earnings growth,” said Jean-Jacques Bienaimé, President and CEO of BioMarin. “In addition to the vast global experience they bring, they are also committed to supporting our work to transform patients’ lives through genetic discoveries.”

Humaira Serajuddin appointed to newly created role of Senior Vice President, Chief Marketing Officer

Ms. Serajuddin brings deep and extensive business experience, having held both operational and strategic positions in roles across multiple functions, as well as international experience in multiple specialty areas. She also has an outstanding track record in leading specialty product launches into larger, more competitive markets. In this newly created role, Ms. Serajuddin is responsible for driving the evolution of BioMarin’s overall product strategy and lifecycle management to prepare BioMarin for the expected transformational growth as the company moves into more competitive and larger markets. . Ms. Serajuddin will work closely with cross-functional teams to define strategy and execute business objectives.

Ms. Serajuddin brings over 20 years of extensive business experience in the pharmaceutical industry, including holding cross-functional roles in areas such as corporate strategy and R&D. Most recently, she spent over ten years with GlaxoSmithKline plc (GSK) in progressively responsible leadership roles at global and country levels. She recently led the very successful launch of a blockbuster therapy at GSK. During her tenure, she also led audit and assurance for the Americas and global R&D, overseeing key enterprise risks, and she was responsible for business strategy and planning for the office of the President of Global R&D and Vaccines, driving business improvement and transformation initiatives. . Prior to GSK, Humaira worked at Novartis AG in sales and marketing roles after spending the early part of his career in clinical research. She holds a bachelor’s degree in biology from Barnard College and an MBA in Marketing and Finance from New York University.

“The arrival of Humaira speaks volumes about the promise of the BioMarin pipeline to deliver breakthrough therapies to larger patient populations, as well as the strength of the company’s core business. His global marketing experience at leading pharmaceutical companies will be integral to the ramp-up of our current product by BioMarin. launch and prepare for future launches,” said Jeff Ajer, Executive Vice President, Chief Commercial Officer at BioMarin. “I look forward to working closely with Humaira during this transformational time at BioMarin.

“I am delighted to join BioMarin at this exciting time as the commercial organization prepares to implement the company’s promising pipeline of potentially breakthrough drugs. I am deeply moved by the company’s goal of transforming lives through its scientific expertise in genetics. I am also drawn to the collegial and caring culture,” said Humaira Serajuddin, Senior Vice President, Chief Marketing Officer at BioMarin. “With its roots in rare diseases, few, if any, companies are as well positioned as BioMarin to have a meaningful impact on more people with genetic diseases.”

Erin Burkhart appointed Group Vice President and Chief Accounting Officer

Ms. Burkhart is a highly experienced accounting and finance executive with deep technical accounting skills, global corporate finance experience, biopharmaceutical business acumen and leadership abilities. She brings a strong accounting background in a number of specialist areas, large-scale enterprise operating model experience and a successful track record of leading transformational business initiatives. In this role, Ms. Burkhart will assume key accounting responsibilities, including setting BioMarin’s global accounting vision and strategy, team leadership, global control and accounting operations and systems, and maintaining policies. accounting and financial internal controls. Ms. Burkhart will be a key member of the management team that will lead the financial aspects of BioMarin’s planned transformational growth.

With more than 20 years of accounting and finance experience, Ms. Burkhart has recently held increasingly responsible accounting positions at Eli Lilly & Co., including leading accounting operations after director of accounting, gross income in the United States. , technical accounting and corporate auditing services. Previously, Ms. Burkhart was Director of Financial Reporting for Stonegate Mortgage Corp and Director of Technical Accounting at Anthem, Inc., and began her career in public accounting at Arthur Andersen & Deloitte. Ms. Burkhart is a CPA and holds a BS in accounting from Butler University.

“It is a pleasure to welcome Erin to BioMarin, where she will be an integral part of supporting our next phase of growth and leading our global accounting function as BioMarin evolves towards sustainable profitability. “, said Brian R. Mueller, Executive Vice President, Chief Financial Officer. “The depth and breadth of Erin’s experience in accounting and the biopharmaceutical industry will be a critical part of the financial foundation that supports our business aspirations of continued product approvals and innovative pipeline growth. , while at the same time generating sustainable increases in revenue, profit and operating cash flow with the goal of continued growth in this decade.”

“I am thrilled to be part of an organization that is developing therapies that make a meaningful difference in the lives of people with genetic diseases. Comptrollership is a strategic partner for our critical research and development, technical and commercial operations. , especially as the company plans to transition to sustainable GAAP profitability,” said Erin Burkhart, Group Vice-Chairman and Chief Accountant. “I look forward to bringing my experience to BioMarin and being part of the vital work BioMarin is doing to advance the standard of care for rare disease patients.”

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with rare diseases and serious and life-threatening medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have a well-understood biology and offer an opportunity to be first to market or offer a significant advantage over existing products. The Company’s portfolio consists of seven commercial products and several clinical and preclinical product candidates for the treatment of various diseases. For more information, please visit

Forward-looking statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: the hiring of Humaira Serajuddin and Erin Burkhart and their anticipated contributions to the Company’s financial, business and regulatory momentum in 2022 and beyond, scaling the organization for sustainable profitability and earnings growth, the promise of the BioMarin pipeline to deliver breakthrough therapies to larger patient populations, the Company’s move towards sustainable profitability, the Company’s expectations for transformational growth, BioMarin’s position to have a meaningful impact on more people with genetic diseases than other companies, and the company’s business aspirations to pursue product approvals and innovative pipeline growth, while generating sustainable increases in revenue, earnings and operating cash flow for continued growth in during this decade.

These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the continued employment of Ms. Serajuddin and Ms. Burkhart as intended, and the factors detailed in BioMarin’s filings with the Securities and Exchange Commission (SEC), including, without limited thereto, the factors contained under the caption “Risk Factors” in BioMarin’s Quarterly Report on Form 10-Q for the Quarter Ended March 31, 2022 as these factors may be updated by any subsequent report. Shareholders are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation and expressly disclaims any obligation to update or change any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin® is a registered trademark of BioMarin Pharmaceutical Inc.


Traci McCarty
BioMarin Pharmaceutical Inc.
(415) 455-7558

Debra Charlesworth
BioMarin Pharmaceutical Inc.
(415) 455-7451



Show original content to download multimedia:–roles-supporting-companys-growth-plans-301540086 .html

SOURCEBioMarin Pharmaceutical Inc.


Comments are closed.